Development
Thermo Fisher Scientific Inc.
TMO
$415.15
$0.610.15%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.63B | 1.72B | 1.36B | 1.29B | 1.58B |
| Total Depreciation and Amortization | 839.00M | 853.00M | 855.00M | 859.00M | 848.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -469.00M | -145.00M | 42.00M | 114.00M | 21.00M |
| Change in Net Operating Assets | 1.72B | -9.00M | -718.00M | -1.53B | 1.04B |
| Cash from Operations | 3.72B | 2.41B | 1.54B | 729.00M | 3.49B |
| Capital Expenditure | -405.00M | -332.00M | -284.00M | -458.00M | -550.00M |
| Sale of Property, Plant, and Equipment | 11.00M | 66.00M | 4.00M | 6.00M | 6.00M |
| Cash Acquisitions | 0.00 | -909.00M | -47.00M | -2.70B | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.00M | -6.00M | -116.00M | 14.00M | 19.00M |
| Cash from Investing | -376.00M | -1.18B | -443.00M | -3.14B | -525.00M |
| Total Debt Issued | 2.48B | 3.47B | 593.00M | 1.03B | 3.49B |
| Total Debt Repaid | -3.78B | -1.49B | -1.92B | -523.00M | 0.00 |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -3.00B | -1.00B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -136.00M | -135.00M | -135.00M | -117.00M | -117.00M |
| Other Financing Activities | 14.00M | 18.00M | 4.00M | 20.00M | 20.00M |
| Cash from Financing | -1.43B | 1.86B | -1.46B | -2.59B | 2.39B |
| Foreign Exchange rate Adjustments | 10.00M | -73.00M | 12.00M | -31.00M | 250.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.93B | 3.02B | -347.00M | -5.04B | 5.60B |